Genomic & Biopharma News

SomaGenics Granted New Patents for RNA Detection and RNA-based Therapeutics Technologies
SomaGenics, an RNA-focused biotechnology company, announced expansion of its intellectual property portfolio with issue of two new patents for its RNA analysis technologies (miR-ID® and RealSeq®) and European patent protection for its therapeutic short synthetic hairpin RNA (sshRNA) agents. MiR-ID®, SomaGenics’ core technology for quantitative real-time PCR, enables accurate analysis of microRNAs (miRNAs) and single-nucleotide ...
Transcriptome Research & Industry News, 2016-12-01 10:00:02

AstraZeneca inks big, backloaded deal for bicyclic peptides
AstraZeneca inks big, backloaded deal for bicyclic peptides nick.paul.taylor Thu, 12/01/2016 - 04:53
Fierce Biotech, 2016-12-01 09:53:04

Alcohol consumption linked to higher risk of melanoma
Alcohol intake was associated with higher rates of invasive melanoma among white men and women.
News Medical Life Sciences, 2016-12-01 09:22:21

Cancer research gets £226 million investment
Cancer Research UK has committed funding of £190 million over the next five years for its network of 13 UK Centres, which aim to accelerate the pathway for getting cutting edge discoveries from the laboratory to patients.
PharmaTimes, 2016-12-01 09:18:21

After Juno deaths, Bluebird posts positive CAR-T safety, efficacy signals
After Juno deaths, Bluebird posts positive CAR-T safety, efficacy signals badams Thu, 12/01/2016 - 02:12
Fierce Biotech, 2016-12-01 07:12:20

Conditional EU nod for Takeda’s Ninlaro
Takeda Pharmaceutical's Ninlaro has been awarded conditional marketing approval in Europe as a second-line treatment for multiple myeloma.
PharmaTimes, 2016-12-01 07:04:42

NICE backs GSK’s novel asthma biologic
It is looking likely that some patients with a difficult-to-treat form of asthma will get routine access to a novel treatment option on the NHS, after GlaxoSmithKline Nucala's was backed by cost regulators.
PharmaTimes, 2016-12-01 07:01:08

AbbVie’s risankizumab bags Orphan status for paediatric Crohn’s
An experimental therapy being developed by AbbVie for paediatric patients with Crohn's disease has been awarded Orphan Drug status in the US.
PharmaTimes, 2016-12-01 06:50:38

Hunt announces £1m pilot scheme to retain GPs over 55
Health secretary Jeremy Hunt has announced a £1 million pilot scheme to encourage GPs nearing retirement to stay in practice by increasing work flexibility and variety.
PharmaTimes, 2016-12-01 06:45:31